

10/549959

JC17 Rec'd PCT/PTO Docket 17712(AP) 15 SEP 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Old et al

Examiner:

Serial No.: Applied for

Group Art Unit:

Filed: Applied for

For: PROSTAGLANDIN ANALOGS

INFORMATION DISCLOSURE STATEMENT

Mailstop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled PROSTAGLANDIN ANALOGS, which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.


10/549959

JC17 Rec'd PCT/PTO ^{Docket 17712 (AP)} 15 SEP 2005

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: 9/14/05



Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date September 1, 2004, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV616152380US addressed to Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BONNIE FERGUSON
Name of person mailing paper

Date 9/15/05

Bonnie Ferguson
Signature of person signing paper

JC17 Rec'd PCT/PTO 15 SEP 2005

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17712(AP)	SERIAL NO.: Applied for 10/549959
APPLICANT: Old et al	TITLE: PROSTAGLANDIN ANALOGS
FILING DATE: Applied for	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,446,041	8/29/1995	Chan et al.			
	AB	5,028,624	7/2/1991	Chan et al.			
	AC	5,034,413	7/23/1991	Chan et al.			
	AD	4,994,274	2/19/1991	Chan et al.			
	AE	4,256,108	3/17/1981	Theeuwes			
	AF	4,166,452	9/4/1979	Generales			
	AG	4,265,874	5/5/1981	Bonsen et al.			
	AH	6,747,037	6/8/2004	Old et al			
	AI	10/861,957	6/3/2004	Old et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	05086034	1993	Japan			

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Bito, L.Z. <u>Biological Protection with Prostaglandins</u> , Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252
	CB	Bito, L.Z., <u>Applied Pharmacology in the Medical Treatment of Glaucomas</u> Drance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp. 477-505
	CC	Bito, L.Z., Prostaglandins Old concepts and new perspectives, <i>Arch Ophthalmol</i> , Vol 105, pp. 1036-1039 (1987)
	CD	Carey, Francis A., Organic Chemistry, New York: McGraw-Hill Book Company 1987, p. 63
	CE	Nilsson, S., et al., PGF2 increases uveoscleral outflow, <i>Invest Ophthalmic Vis Sci. (suppl)</i> 284 ARVO Abstracts, 1987
	CF	Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 16th Edition, 1980
	CG	Siebold, et al., Esterfied prostaglandin shows 'potent' promise, <i>Prodrug</i> , (5) 3 (1989)
	CH	Almstead et al (J. Med. Chem., 42 (22), 4547-4562
	CI	Chourasia and Jain in J Pharm Pharmaceut Sci 6 (1): 33-66, 2003
	CJ	Shareef et. al (AAPS PharmSci 2003; 5 (2) Article 17); 161-186
	CK	Old results, pages 1-8

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.